No real transactions

Deucrictibant

Research only

on-demand treatment of hereditary angioedema attacks

Search PubMedNCT06343779Publications

Published evidence

2 publications2 exact-program0 related1 context / correction notes

Review publications

Program details

Sponsor describes an oral small-molecule B2 antagonist, RAPIDe-3 and an April 23, 2027 FDA target.

Program names
deucrictibant
Modality
Small molecule
Indication
on-demand treatment of hereditary angioedema attacks
Associated trial
NCT06343779
FDA target
April 23, 2027Date-only guidance; not a trading cutoff.

Publications 2

Evidence is grouped by its relationship to this program.

Search PubMed

Publication notes explain the evidence behind this program. PubMed / NCBI data notice

Coverage & interpretation
  • Both selected clinical papers concern the immediate-release on-demand HAE program.
  • Prophylaxis and acquired-angioedema papers are not treated as exact-program evidence.

Exact program / indication

2 records
Exact programhuman clinicalPMID 42849489

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

Lancet (London, England) · 2026-10-08

RAPIDe-3 used a randomized, placebo-controlled crossover design to study oral deucrictibant during HAE attacks. The abstract reports faster symptom relief with the immediate-release capsule and no severe or serious treatment-related adverse events in the study.

Program relevance

Phase 3 RAPIDe-3 (NCT06343779) tests the catalog immediate-release, on-demand hereditary-angioedema program.

Formulation / population: 20 mg oral immediate-release deucrictibant for on-demand HAE attacks.

Journal Article / Clinical Trial, Phase III / Randomized Controlled Trial / Multicenter Study

PubMedPublisher / DOI
Exact programhuman clinicalPMID 41865747

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Haematology · 2026-03-19

This randomized, placebo-controlled, dose-ranging crossover trial studied immediate-release deucrictibant during HAE attacks. Symptom-severity scores improved compared with placebo, supporting further investigation of the on-demand program.

Program relevance

Earlier phase 2 RAPIDe-1 (NCT04618211) evaluates immediate-release oral deucrictibant for on-demand HAE attacks.

Formulation / population: Oral immediate-release deucrictibant at 10, 20 or 30 mg during HAE attacks.

  • Earlier phase 2 cohort, distinct from RAPIDe-3.

Journal Article / Randomized Controlled Trial / Clinical Trial, Phase II / Multicenter Study

PubMedPublisher / DOI

Sources

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseir.pharvaris.com
Sponsor describes an oral small-molecule B2 antagonist, RAPIDe-3 and an April 23, 2027 FDA target.
Published
Jul 6, 2026
Retrieved
2026-10-30 02:09:48 UTC
clinical-trial-registryclinicaltrials.gov
Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.
Published
Not supplied
Retrieved
2026-10-30 02:09:48 UTC

Research identity and publications do not establish regulatory approval, clinical suitability or an executable market. Read the limits